Pediatric brachytherapy. The St. Jude children's research hospital experience

James Fontanesi, Bhaskar N. Rao, Irvin D. Fleming, Laura C. Bowman, Charles B. Pratt, Wayne L. Furman, Douglas H. Coffey, Larry E. Kun

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The use of interstitial, intracavitary, and permanent placement of radioactive isotopes has become a common practice in adult oncology patients based on numerous reports indicating improved local control and survival when used.1–4 These same irradiation techniques and treatments have been infrequently used for children with malignant disease despite known dose localization properties that allow for highly focal irradiation delivery with rapid reduction of the dose in nearby normal tissues. The noted benefit of decreased late complications noted in the adult series is also attractive, especially when considering the treatment of children. Methods: Between May, 198,1 and December 15, 1992, 46 children with non‐CNS primary malignancy received 50 brachytherapy applications for primary therapy (n = 11 sites), as a boost in conjunction with external beam irradiation (n = 16 sites), or as treatment of recurrent disease or a second malignant neoplasm in a previously irradiated region that precluded further external irradiation or for metastatic disease (n = 23 sites). The most common tumor histologies were rhabdomyosarcoma (n = 14), soft tissue sarcoma (n = 10) and retinoblastoma (n = 10). Patient age at implantation ranged from 8 weeks to 24 years; follow‐up was maintained in all patients and has ranged from 2–115 months (median, 39 months). Results: Forty‐three of 50 sites receiving brachytherapy have maintained continuous disease free intervals, ranging from 2 to 115 months postimplantation (median, 41 months). The seven local failures occurred 2–20 months postimplant (median, 6 months). Severe complications occurred in 12 patients, two which were life threatening but resolved without further incident. Conclusions: Based on this ongoing clinical investigation, the authors recommend brachytherapy for selected pediatric malignancies and continue to evaluate the various factors associated with local control, local failures, and complications. Cancer 1994; 74: 733‐9.

Original languageEnglish (US)
Pages (from-to)733-739
Number of pages7
JournalCancer
Volume74
Issue number2
DOIs
StatePublished - Jan 1 1994

Fingerprint

Brachytherapy
Pediatrics
Research
Neoplasms
Second Primary Neoplasms
Rhabdomyosarcoma
Retinoblastoma
Therapeutics
Radioisotopes
Sarcoma
Histology
Survival

Keywords

  • brachytherapy
  • interstitial irradiation
  • pediatric

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pediatric brachytherapy. The St. Jude children's research hospital experience. / Fontanesi, James; Rao, Bhaskar N.; Fleming, Irvin D.; Bowman, Laura C.; Pratt, Charles B.; Furman, Wayne L.; Coffey, Douglas H.; Kun, Larry E.

In: Cancer, Vol. 74, No. 2, 01.01.1994, p. 733-739.

Research output: Contribution to journalArticle

Fontanesi, J, Rao, BN, Fleming, ID, Bowman, LC, Pratt, CB, Furman, WL, Coffey, DH & Kun, LE 1994, 'Pediatric brachytherapy. The St. Jude children's research hospital experience', Cancer, vol. 74, no. 2, pp. 733-739. https://doi.org/10.1002/1097-0142(19940715)74:2<733::AID-CNCR2820740229>3.0.CO;2-A
Fontanesi, James ; Rao, Bhaskar N. ; Fleming, Irvin D. ; Bowman, Laura C. ; Pratt, Charles B. ; Furman, Wayne L. ; Coffey, Douglas H. ; Kun, Larry E. / Pediatric brachytherapy. The St. Jude children's research hospital experience. In: Cancer. 1994 ; Vol. 74, No. 2. pp. 733-739.
@article{da3b79834c1a4f26ae575d9d6fba60e8,
title = "Pediatric brachytherapy. The St. Jude children's research hospital experience",
abstract = "Background: The use of interstitial, intracavitary, and permanent placement of radioactive isotopes has become a common practice in adult oncology patients based on numerous reports indicating improved local control and survival when used.1–4 These same irradiation techniques and treatments have been infrequently used for children with malignant disease despite known dose localization properties that allow for highly focal irradiation delivery with rapid reduction of the dose in nearby normal tissues. The noted benefit of decreased late complications noted in the adult series is also attractive, especially when considering the treatment of children. Methods: Between May, 198,1 and December 15, 1992, 46 children with non‐CNS primary malignancy received 50 brachytherapy applications for primary therapy (n = 11 sites), as a boost in conjunction with external beam irradiation (n = 16 sites), or as treatment of recurrent disease or a second malignant neoplasm in a previously irradiated region that precluded further external irradiation or for metastatic disease (n = 23 sites). The most common tumor histologies were rhabdomyosarcoma (n = 14), soft tissue sarcoma (n = 10) and retinoblastoma (n = 10). Patient age at implantation ranged from 8 weeks to 24 years; follow‐up was maintained in all patients and has ranged from 2–115 months (median, 39 months). Results: Forty‐three of 50 sites receiving brachytherapy have maintained continuous disease free intervals, ranging from 2 to 115 months postimplantation (median, 41 months). The seven local failures occurred 2–20 months postimplant (median, 6 months). Severe complications occurred in 12 patients, two which were life threatening but resolved without further incident. Conclusions: Based on this ongoing clinical investigation, the authors recommend brachytherapy for selected pediatric malignancies and continue to evaluate the various factors associated with local control, local failures, and complications. Cancer 1994; 74: 733‐9.",
keywords = "brachytherapy, interstitial irradiation, pediatric",
author = "James Fontanesi and Rao, {Bhaskar N.} and Fleming, {Irvin D.} and Bowman, {Laura C.} and Pratt, {Charles B.} and Furman, {Wayne L.} and Coffey, {Douglas H.} and Kun, {Larry E.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19940715)74:2<733::AID-CNCR2820740229>3.0.CO;2-A",
language = "English (US)",
volume = "74",
pages = "733--739",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Pediatric brachytherapy. The St. Jude children's research hospital experience

AU - Fontanesi, James

AU - Rao, Bhaskar N.

AU - Fleming, Irvin D.

AU - Bowman, Laura C.

AU - Pratt, Charles B.

AU - Furman, Wayne L.

AU - Coffey, Douglas H.

AU - Kun, Larry E.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background: The use of interstitial, intracavitary, and permanent placement of radioactive isotopes has become a common practice in adult oncology patients based on numerous reports indicating improved local control and survival when used.1–4 These same irradiation techniques and treatments have been infrequently used for children with malignant disease despite known dose localization properties that allow for highly focal irradiation delivery with rapid reduction of the dose in nearby normal tissues. The noted benefit of decreased late complications noted in the adult series is also attractive, especially when considering the treatment of children. Methods: Between May, 198,1 and December 15, 1992, 46 children with non‐CNS primary malignancy received 50 brachytherapy applications for primary therapy (n = 11 sites), as a boost in conjunction with external beam irradiation (n = 16 sites), or as treatment of recurrent disease or a second malignant neoplasm in a previously irradiated region that precluded further external irradiation or for metastatic disease (n = 23 sites). The most common tumor histologies were rhabdomyosarcoma (n = 14), soft tissue sarcoma (n = 10) and retinoblastoma (n = 10). Patient age at implantation ranged from 8 weeks to 24 years; follow‐up was maintained in all patients and has ranged from 2–115 months (median, 39 months). Results: Forty‐three of 50 sites receiving brachytherapy have maintained continuous disease free intervals, ranging from 2 to 115 months postimplantation (median, 41 months). The seven local failures occurred 2–20 months postimplant (median, 6 months). Severe complications occurred in 12 patients, two which were life threatening but resolved without further incident. Conclusions: Based on this ongoing clinical investigation, the authors recommend brachytherapy for selected pediatric malignancies and continue to evaluate the various factors associated with local control, local failures, and complications. Cancer 1994; 74: 733‐9.

AB - Background: The use of interstitial, intracavitary, and permanent placement of radioactive isotopes has become a common practice in adult oncology patients based on numerous reports indicating improved local control and survival when used.1–4 These same irradiation techniques and treatments have been infrequently used for children with malignant disease despite known dose localization properties that allow for highly focal irradiation delivery with rapid reduction of the dose in nearby normal tissues. The noted benefit of decreased late complications noted in the adult series is also attractive, especially when considering the treatment of children. Methods: Between May, 198,1 and December 15, 1992, 46 children with non‐CNS primary malignancy received 50 brachytherapy applications for primary therapy (n = 11 sites), as a boost in conjunction with external beam irradiation (n = 16 sites), or as treatment of recurrent disease or a second malignant neoplasm in a previously irradiated region that precluded further external irradiation or for metastatic disease (n = 23 sites). The most common tumor histologies were rhabdomyosarcoma (n = 14), soft tissue sarcoma (n = 10) and retinoblastoma (n = 10). Patient age at implantation ranged from 8 weeks to 24 years; follow‐up was maintained in all patients and has ranged from 2–115 months (median, 39 months). Results: Forty‐three of 50 sites receiving brachytherapy have maintained continuous disease free intervals, ranging from 2 to 115 months postimplantation (median, 41 months). The seven local failures occurred 2–20 months postimplant (median, 6 months). Severe complications occurred in 12 patients, two which were life threatening but resolved without further incident. Conclusions: Based on this ongoing clinical investigation, the authors recommend brachytherapy for selected pediatric malignancies and continue to evaluate the various factors associated with local control, local failures, and complications. Cancer 1994; 74: 733‐9.

KW - brachytherapy

KW - interstitial irradiation

KW - pediatric

UR - http://www.scopus.com/inward/record.url?scp=0028181334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028181334&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940715)74:2<733::AID-CNCR2820740229>3.0.CO;2-A

DO - 10.1002/1097-0142(19940715)74:2<733::AID-CNCR2820740229>3.0.CO;2-A

M3 - Article

VL - 74

SP - 733

EP - 739

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -